Resverlogix Corp. (RVX) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.013x

Based on the latest financial reports, Resverlogix Corp. (RVX) has a cash flow conversion efficiency ratio of 0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-1.12 Million ≈ $-812.98K USD) by net assets (CA$-85.83 Million ≈ $-62.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Resverlogix Corp. - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how Resverlogix Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Resverlogix Corp. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Resverlogix Corp. ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Resverlogix Corp. (2001–2024)

The table below shows the annual cash flow conversion efficiency of Resverlogix Corp. from 2001 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CA$-81.73 Million
≈ $-59.13 Million
CA$-3.89 Million
≈ $-2.81 Million
0.048x +35.51%
2023-12-31 CA$-74.47 Million
≈ $-53.87 Million
CA$-2.61 Million
≈ $-1.89 Million
0.035x -41.26%
2022-12-31 CA$-59.28 Million
≈ $-42.88 Million
CA$-3.54 Million
≈ $-2.56 Million
0.060x -55.43%
2021-12-31 CA$-59.87 Million
≈ $-43.31 Million
CA$-8.02 Million
≈ $-5.80 Million
0.134x +121392.30%
2020-12-31 CA$-39.90 Million
≈ $-28.86 Million
CA$-4.40K
≈ $-3.18K
0.000x -99.96%
2019-12-31 CA$-64.11 Million
≈ $-46.38 Million
CA$-17.34 Million
≈ $-12.55 Million
0.271x +15.07%
2018-12-31 CA$-207.72 Million
≈ $-150.26 Million
CA$-48.83 Million
≈ $-35.33 Million
0.235x -21.73%
2017-12-31 CA$-83.68 Million
≈ $-60.53 Million
CA$-25.13 Million
≈ $-18.18 Million
0.300x +34.58%
2016-12-31 CA$-101.57 Million
≈ $-73.47 Million
CA$-22.67 Million
≈ $-16.40 Million
0.223x -41.21%
2015-12-31 CA$-56.43 Million
≈ $-40.82 Million
CA$-21.42 Million
≈ $-15.50 Million
0.380x +229.32%
2014-12-31 CA$-73.73 Million
≈ $-53.33 Million
CA$-8.50 Million
≈ $-6.15 Million
0.115x -44.80%
2013-12-31 CA$-63.22 Million
≈ $-45.73 Million
CA$-13.20 Million
≈ $-9.55 Million
0.209x -78.75%
2012-12-31 CA$-29.50 Million
≈ $-21.34 Million
CA$-29.00 Million
≈ $-20.98 Million
0.983x +111.21%
2011-12-31 CA$2.74 Million
≈ $1.98 Million
CA$-24.03 Million
≈ $-17.38 Million
-8.766x -95.92%
2010-12-31 CA$4.30 Million
≈ $3.11 Million
CA$-19.24 Million
≈ $-13.92 Million
-4.474x -8.91%
2009-12-31 CA$4.46 Million
≈ $3.23 Million
CA$-18.34 Million
≈ $-13.26 Million
-4.108x -266.55%
2008-12-31 CA$11.61 Million
≈ $8.40 Million
CA$-13.01 Million
≈ $-9.41 Million
-1.121x +68.96%
2007-12-31 CA$5.44 Million
≈ $3.94 Million
CA$-19.65 Million
≈ $-14.21 Million
-3.611x -137.13%
2006-12-31 CA$-1.02 Million
≈ $-738.42K
CA$-9.93 Million
≈ $-7.18 Million
9.724x +1749.37%
2005-12-31 CA$7.48 Million
≈ $5.41 Million
CA$-4.41 Million
≈ $-3.19 Million
-0.590x -166.26%
2004-12-31 CA$9.84 Million
≈ $7.12 Million
CA$-2.18 Million
≈ $-1.58 Million
-0.221x +35.03%
2003-12-31 CA$2.60 Million
≈ $1.88 Million
CA$-885.04K
≈ $-640.23K
-0.341x +29.20%
2002-12-31 CA$942.21K
≈ $681.58K
CA$-453.56K
≈ $-328.10K
-0.481x -1038.52%
2001-12-31 CA$259.64K
≈ $187.82K
CA$-10.98K
≈ $-7.94K
-0.042x --

About Resverlogix Corp.

TO:RVX Canada Biotechnology
Market Cap
$20.79 Million
CA$28.73 Million CAD
Market Cap Rank
#24905 Global
#975 in Canada
Share Price
CA$0.10
Change (1 day)
+0.00%
52-Week Range
CA$0.04 - CA$0.23
All Time High
CA$4.79
About

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary sy… Read more